echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Treating seasonal influenza genetically modified cattle to help produce broad-spectrum antibody therapies

    Treating seasonal influenza genetically modified cattle to help produce broad-spectrum antibody therapies

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Today, SAB Biotherapeutics announced that its polyclonal antibody therapy SAB-176 for the treatment of seasonal influenza has reached its primary endpoint in a Phase 2a clinical trial for the treatment of seasonal influenza
    Among adults who were challenged by the virus, SAB-176 significantly reduced the viral load and clinical symptoms compared with placebo
    It is worth mentioning that the company's technology platform uses genetically engineered cattle to produce fully humanized polyclonal antibodies
    This result is also a clinical proof of concept for this technology platform

    Influenza virus infection is one of the most common infectious diseases, causing 2.
    5 to 5 million hospitalizations worldwide every year
    Due to the rapid mutation of the influenza virus, the current influenza vaccine does not provide high protection effectiveness, and there are not many approved drugs for the treatment of influenza

    SAB-176 is a fully humanized broad-spectrum neutralizing polyclonal antibody
    Unlike monoclonal antibodies, polyclonal antibodies contain a variety of different antibody types, which target a variety of different antigens associated with influenza viruses
    Pre-clinical studies have shown that it can have a wide range of protective effects on different influenza virus strains

    SAB Biotherapeutics' technology platform uses genetically engineered cattle to produce a large number of fully humanized antibodies.
    By inoculating cattle with different pathogens, they can produce polyclonal antibodies that target specific pathogens

    In this randomized, double-blind, placebo-controlled Phase 2a clinical trial, healthy volunteers received SAB-176 or placebo and were nasally inoculated with H1N1 influenza virus.
    Eight days after the inoculation, the nasopharyngeal swab samples The analysis of the viral load in SAB-176 found that compared with placebo, patients treated with SAB-176 had a significantly lower H1N1 viral load (one-sided p=0.

    In addition, in patients with symptoms, SAB-176 significantly reduced the clinical symptoms of influenza compared with placebo (one-sided p=0.

    In this study, SAB-176 showed good safety and tolerability, no serious adverse events related to it were observed, and most of the adverse events were mild or moderate

    Reference materials:

    [1] SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus.
    Retrieved December 1, 2021, from https://ir.
    com/news-releases/news-release- details/sab-biotherapeutics-announces-sab-176-met-its-primary-endpoint

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.